BioXcel Therapeutics
BTAI
108 hedge funds and large institutions have $512M invested in BioXcel Therapeutics in 2020 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 21 reducing their positions, and 21 closing their positions.
227% more call options, than puts
Call options by funds: $23.3M | Put options by funds: $7.13M
138% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 21
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
19% more capital invested
Capital invested by funds: $431M → $512M (+$81.2M)
4% more funds holding
Funds holding: 104 → 108 (+4)
0.81% more ownership
Funds ownership: 2.51% → 3.32% (+0.81%)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$82.6M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$27.6M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$20.4M |
| 4 |
State Street
Boston,
Massachusetts
|
+$15M |
| 5 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$14.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$18.1M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$12.7M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$12.5M |
| 4 |
Renaissance Technologies
New York
|
-$8.25M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$7.95M |
BTAI Hedge Fund Activity: Q3 2020 in Review
108 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2020, worth a combined $512M — up 19% from $431M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BTAI positions and 21 closed out — a net gain of 4 holders — while 50 added to existing stakes and 21 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $82.6M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $18.1M sold.
- 108 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2020, up from 104 in Q2 2020.
- Funds reported $512M of BioXcel Therapeutics stock for Q3 2020, up 19% quarter-over-quarter.
- 25 funds opened new BioXcel Therapeutics positions in Q3 2020 and 21 closed out, a net change of +4 holders.
- The largest BioXcel Therapeutics buyer in Q3 2020 was Fidelity Investments, an estimated $82.6M added.
- The largest BioXcel Therapeutics seller in Q3 2020 was Acuta Capital Partners, an estimated $18.1M sold.
Based on aggregated 13F filings for Q3 2020.